We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Submit a Manuscript to the Journal
Human Vaccines & Immunotherapeutics

For a Special Issue on
Patient-specific anti-cancer immunotherapies

Manuscript deadline
03 March 2023

Cover image - Human Vaccines & Immunotherapeutics

Special Issue Editor(s)

Robert O. Dillman, MD, AIVITA Biomedical, Inc. and University of California Irvine
[email protected]

Submit an ArticleVisit JournalArticles

Patient-specific anti-cancer immunotherapies

The following are appropriate products for inclusion in this focused issue:

*Autologous anti-cancer vaccines: such as autologous vaccines derived from whole tumor or autologous tumor derived heat shock proteins, autologous dendritic cell vaccines including autologous dendritic cells loaded with other antigens/adjuvants (such as sipuleucel-T) and autologous dendritic cells loaded with autologous tumor antigens (whether from autologous whole tumor, allogeneic tumor, autologous tumor cell line, or selected neoantigens)Β  or autologous dendritic cell vaccines loaded with a combination of antigens based on tumor phenotype.

*Autologous tumor infiltrating lymphocytes

*Autologous lymphokine activated killer (LAK) cells or cytokine-induced killer (CIK) cells, or autologous natural killer cells

*CART or TCR autologous cytotoxic T lymphocytes

*Intratumor injections of immune stimulating agents such as talimogene lahareparvec (TVEC)

Submission Instructions

Special Issue Title: Patient-specific anti-cancer immuotherapies

Review articles are preferred, but research articles and commentaries are also accpetable.

Submit as soon as possible,; expected publication date by end of Q1 2023

Instructions for AuthorsSubmit an Article

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.